The Respiratory syncytial virus (RSV) is highly contagious.
Babies, small children and elderly people are most at risk.
RSV can cause upper respiratory infections (such as colds) and lower respiratory tract infections (such as bronchiolitis and pneumonia) and in most severe cases, become life-threatening.
You can be infected with RSV several times during your lifetime. After each RSV infection, your body becomes more immune to the virus, but you are never completely immune.
a medical, societal, and economic burden
RSV is associated with substantial disease burden in infants, young children, and the elderly.
Globally, an estimated 33 million young children are diagnosed with RSV disease each year, with over 3 million cases requiring hospitalisation.
RSV disease accounts for hospitalisation of 1 in 5 young children under 5 years of age diagnosed with acute lower respiratory infection (ALRI).
Annually, RSV causes an estimated 118,000 child deaths worldwide.
Every year about 3-6% of all older adults are infected with RSV.
RSV poses substantial burden on healthcare services including hospitalisations and outpatient consultations and in industrialised countries about 8% of hospitalised cases are likely to die.
Of all acute respiratory track infection patients, RSV accounted for 1-10% in adults and 2-14% in patients with chronic diseases or transplantation.
Childhood RSV costs governments around the world nearly 5 billion euros every year.
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement 101034339. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
The Innovative Medicines Initiative is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). It is working to improve health by speeding up the development of the next generation of medicines, particularly in areas where there is an unmet medical or social need. It works by facilitating collaboration between the key players involved in health research, including universities, research centres, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. IMI is the world’s biggest public-private partnership (PPP) in the life sciences.
Collect information about user navigation through the site in order to know the origin of the visits and other similar data at a statistical level.